1 / 15

DNDi Update: Global Partnership Addressing Needs of Most Neglected From Research to Access

DNDi Update: Global Partnership Addressing Needs of Most Neglected From Research to Access. Dr Monique Wasunna KEMRI/Head of DNDi Africa AEMI meeting Cape Town December 13-15 2010. DNDi’s HISTORY. 1999

loe
Télécharger la présentation

DNDi Update: Global Partnership Addressing Needs of Most Neglected From Research to Access

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DNDi Update: Global PartnershipAddressingNeedsof Most NeglectedFromResearch to Access Dr Monique Wasunna KEMRI/Head of DNDi Africa AEMI meeting Cape Town December 13-15 2010

  2. DNDi’s HISTORY • 1999 • First meeting in Paris to describe the lack of R&D for neglected diseases (the day MSF received the Nobel Peace Prize) • MSF commits the Nobel Peace Prize money to the Drugs for Neglected Diseases Working Group • Jama’s article (01/27/99), “Access to essential drugs in poor countries - A  Lost Battle?”, B. Pécoul and all. • 2001 • DND WG recommends the creation of DNDi • July 2003 • Creation of DNDi (7 founding members

  3. A New Model for Drug Development: DNDi created in 2003 • Non-profit drug research & development (R&D) organization founded in 2003 • Addressing the needs of the most neglected patients • Harnessing resources from public institutions, private industry and philanthropic entities 7 worldwide offices • 7 Founding Partners • Indian Council for Medical Research (ICMR) • Kenya Medical Research Institute (KEMRI) • Malaysian MOH • Oswaldo Cruz Foundation Brazil • Medecins Sans Frontieres (MSF) • Institut Pasteur France • WHO/TDR (permanent observer) Japan USA India DRC Malaysia Geneva Coordination Team + consultants Kenya Brazil

  4. VISION • To improve the quality of life and health of people suffering from neglected diseases - by using an alternative model to develop drugs for these diseases - ensuring equitable access to new and field relevant health tools - not for profit model driven by public sector and partners - build public responsibility and leadership in addressing the needs of these patients

  5. MISSION • To develop new drugs or new formulations of existing drugs for patients suffering from the most neglected diseases

  6. DNDi’s Main Objectives • Deliver 6 to 8 new treatments by 2014 for sleeping sickness, Chagas disease, leishmaniasis and malaria • Establish a robust pipeline for future needs • Use and strengthen existing capacity in disease-endemic countries • Raise awareness and advocate for increased public responsibility

  7. 7-Year Results • 2 new malaria treatments • 1 new sleeping sickness combination • 1 new visceral leishmaniasis combination for Africa • Largest pipeline ever for the kinetoplastid diseases • Clinical research platforms in Africa • On track to deliver new treatments per business plan

  8. CURRENT STATUS • 4 treatments delivered - 2007 fixed dose Artesunate/Amodaiaquine (ASAQ) Sanofi Aventis(France) - 2008 ASMQ Farmanguinhos and Cipla - 2009 Nifurtimox/Eflornithine co adminstration (NECT) National Control programmes, MSF/Epicentre, Bayer, Sanofi Aventis, WHO -2010 SSG+Paromomycin combination RX for VL in EA now recommended by WHO and MOH Sudan has recommended as first line Rx for VL

  9. Challenges to build innovation and research capacities in Africa • Public leadership to define R&D priorities • Significant investment with sustainable funding • Ensure better access to knowledge and promote innovative IP management policies • Enable more adapted regulatory environment • Transfer technology and strengthen research capacities in developing countries

  10. By working together in a creative way, south south can bring innovation to neglected patients! Thank you

  11. VL Objectives: SUDAN: 2 sites (Kassab, Dooka) Univ. of Khartoum Federal Ministry of Health ETHIOPIA: 2 sites (Gondar, Arba Minch) Addis Ababa Univ. Gondar Univ. Ministry of Health Partners: MSF I+ solutions LSH&TM AMC/ SU/ KIT (ASK) IOWH - India Industry partners KENYA: 2 sites (Nairobi, Kimalel) KEMRI Ministry of Health • UGANDA: 1 site (Amudat) • Makerere Univ. • Ministry of Health

  12. LEAPObjectives Facilitate clinical testing and registration of new treatments for VL in the region (Ethiopia, Kenya, Sudan and Uganda) Evaluate, validate and register improved options that address regional needs for VL Provide capacity strengthening for drug evaluation and clinical studies in the region

  13. Infrastructure upgrades LEAP Activities Capacity strengthening Previous VL Treatment ward Gondar Renovation and re-equipping of clinical laboratories to high standards • Regional pool of clinical trial expertise • Serve as forum for members to share their clinical & research experience • Support the review and roll out of VL National Guidelines for member countries Current VL Treatment centre and Physiotherapy Dept, Gondar

  14. Sharing of experiences between South-South LEAP scientits

  15. HAT Strengthening Clinical Trial Capacity Platform Objectives To strengthen clinical trial capacity for sleeping sickness To overcome health system challenges for clinical research To share information on HAT research progress To improve HAT clinical trial methodologies • Partners: • National HAT control programs of most affected endemic countries • DNDi, STI • Research institutes like ITMA, INRB, CDC, KARI-TRC • NGOs like MSF, Epicentre • FIND, WHO • Regional networks - eg. EANETT, PABIN, AMANET

More Related